Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): A randomised phase 2 trial

The Lancet Oncology

Volumn 16, Issue 8, 2015, Pages 967-978

  Valle, Juan W ^a,b   Wasan, Harpreet ^c   Lopes, Andre ^d   Backen, Alison C ^a   Palmer, Daniel H ^e   Morris, Karen ^e   Duggan, Marian ^d   Cunningham, David ^f   Anthoney, D Alan ^g   Corrie, Pippa ^h   Madhusudan, Srinivasan ⁱ   Maraveyas, Anthony ^j   Ross, Paul J ^k   Waters, Justin S ^l   Steward, Will P ^m   Rees, Charlotte ⁿ   Beare, Sandy ^d   Dive, Caroline ^o   Bridgewater, John A ^p  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^j CASTLE HILL HOSPITAL   (United Kingdom)

^k GUY S HOSPITAL   (United Kingdom)

^l MAIDSTONE HOSPITAL   (United Kingdom)

^m LEICESTER ROYAL INFIRMARY   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CEDIRANIB; CISPLATIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; PLACEBO; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIARY TRACT CANCER; BILIARY TRACT INFECTION; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CHOLESTASIS; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLATULENCE; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HEARING IMPAIRMENT; HEART INFARCTION; HEPATITIS; HEPATOBILIARY DISEASE; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INSOMNIA; LETHARGY; LIFE EXPECTANCY; LIMB PAIN; LUNG INFECTION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPHIL COUNT; ORAL MUCOSITIS; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SORE THROAT; SURVIVAL TIME; THORAX PAIN; THROMBOCYTE COUNT; THROMBOEMBOLISM; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BILIARY TRACT NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938205656     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00139-4     Document Type: Article

References (39)

1. Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol 2012, 56:848-854.
2. Patel T Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353-1357.
3. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 2013, 24:1667-1674.
4. Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7:593-600.
5. Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010, 28:4581-4586.
6. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281. the ABC-02 Trial Investigators.
7. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010, 103:469-474.
8. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008, 98:418-425.
9. Tang D, Nagano H, Yamamoto H, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006, 15:525-532.
10. Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Sivridis E Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol 2003, 29:879-883.
11. Möbius C, Demuth C, Aigner T, et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 2007, 33:1025-1029.
12. Benckert C, Jonas S, Cramer T, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003, 63:1083-1092.
13. Hida Y, Morita T, Fujita M, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res 1999, 19:2257-2260.
14. Shirabe K, Shimada M, Tsujita E, et al. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am J Surg 2004, 187:538-542.
15. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
16. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008, 26:1871-1878.
17. Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C 'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods 2009, 342:106-114.
18. Greystoke A, Cummings J, Ward T, et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 2008, 19:990-995.
19. Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007, 13:920-928.
20. Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010, 102:68-72.
21. Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010, 28:3491-3497.
22. Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11:48-54.
23. Moehler M, Maderer A, Schimanski C, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer 2014, 50:3125-3135. the Working Group of Internal Oncology.
24. Grunnet M, Mau-Sorensen M Serum tumor markers in bile duct cancer: a review. Biomarkers 2014, 19:437-443.
25. Ku NO, Liao J, Omary MB Apoptosis generates stable fragments of human type I keratins. J Biol Chem 1997, 272:33197-33203.
26. Hägg M, Bivén K, Ueno T, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002, 20:253-259.
27. Greystoke A, Dean E, Saunders MP, et al. Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Br J Cancer 2012, 107:1518-1524.
28. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011, 29:1556-1563.
29. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012, 30:525-532.
30. Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 2012, 106:508-516.
31. Morris KL, Tugwood JD, Khoja L, et al. Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol 2014, 74:323-332.
32. Khoja L, Shenjere P, Hodgson C, et al. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res 2014, 24:40-46.
33. Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 2013, 19:1557-1566.
34. Jürgensmeier JM, Schmoll HJ, Robertson JD, et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer 2013, 108:1316-1323.
35. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:3045-3054.
36. Heldin CH, Westermark B Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
37. Fingas CD, Mertens JC, Razumilava N, et al. Targeting PDGFR-beta in cholangiocarcinoma. Liver Int 2012, 32:400-409.
38. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014, 20:897-903.
39. Rothwell DG, Li Y, Ayub M, et al. Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells. BMC Genomics 2014, 15:1129.